

## COMPANY OVERVIEW

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.

## RECENT NEWS

### PharmaCyte Biotech Releases CEO Interview from The Big Biz Show

Jan 22 2019, 9:15 AM EST

## STOCK OVERVIEW

Symbol	PMCB
Exchange	OTCQB
Market Cap	62.88m
Last Price	\$0.0558
52-Week Range	\$0.036 - \$0.105

02/20/2019 03:58 PM EST

## INVESTOR RELATIONS

PharmaCyte Biotech, Inc.  
Investor Relations Department  
T: 917-595-2856  
[Info@PharmaCyte.com](mailto:Info@PharmaCyte.com)

## MANAGEMENT TEAM

### Kenneth L. Waggoner, JD

Chief Executive Officer, President, General Counsel and Chairman of the Board

### Dr. Gerald W. Crabtree

Chief Operating Officer and Director

### Dr. Linda S. Sher

Chief Medical Officer

### Prof. Dr. Walter H. Günzburg

Chief Scientific Officer

### Carlos A. Trujillo, CPA

Chief Financial Officer and Director

### Dr. Matthias Löhr

Medical and Scientific Advisory Board  
Chairman

### Dr. Eva Maria Brandtner

Director of Diabetes Program Development

### Dr. Mark L. Rabe

Director of Cannabis Program  
Development

## PHARMACYTE BIOTECH, INC.

23046 Avenida de la Carlota  
Suite 600  
Laguna Hills, CA 92653  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.